a) an agonist or antagonist of binding to a PTH receptor or PTHrP receptor, and

b) a substance that binds to a ligand of either receptor to promote or inhibit binding between the ligand and the receptor.

2. (Twice Amended) The method according to claim 1, wherein the disease mediated by PTH or PTHrP is a disease other than hypercalcemia.

3. (Twice Amended) The method of claim 1, wherein the disease mediated by PTH or PTHrP reduces the QOL of at least one patient.

4. (Twice Amended) The method of claim 1, wherein the disease is a syndrome associated with malignancy and the syndrome is mediated by PTHrP.

5. (Twice Amended) The method according to claim 4, wherein the syndrome associated with malignancy is chosen from at least one of digestive system disorder, proteometabolism abnormality, saccharometabolism abnormality, lipid metabolism abnormality, anorexia, hematological abnormality, electrolyte abnormality, immunodeficiency and pain.

6. (Twice Amended) The method according to claim 1, wherein the disease is chosen from at least one of

a) secondary hyperparathyroidism and

b) primary hyperparathyroidism.

7. (Twice Amended) The method of claim 1, wherein the disease is at least one central nervous system disease mediated by PTH or PTHrP.

8. (Twice Amended) The method according to claim 7, wherein the central nervous system disease is chosen from at least one of dyssomnia, neuropathy, nervous

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

symptom disorder, brain metabolism abnormality, cerebral circulation abnormality, autonomic imbalance, and endocrine system abnormality with which the central nervous system is associated.

9. (Twice Amended) The method of claim 1, wherein the disease is mediated by PTH- or PTHrP-cytokine cascade.

10. (Twice Amended) The method according to claim 9, wherein the cytokine is chosen from at least one of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL- 15, G-CSF, GM-CSF, M-CSF, EPO, LIF, TPO, EGF, TGF-α, TGF-β, FGF, IGF, HGF, VEGF, NGF, activin, inhibin, a BMP family member, TNF and IFN.

11. (Twice Amended) The method according to claim 9 or 10, wherein the disease mediated by PTH- or PTHrP-cytokine cascade is chosen from at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

12. (Twice Amended) The method of claim 1, wherein the active ingredient is a central nervous system regulator.

13. (Twice Amended) The method of claim 1, wherein the active ingredient is a cytokine network regulator.

14. (Amended) The method according to any one of claims 1 to 10 or 12 to 13, wherein the PTH receptor or PTHrP receptor is a PTH/PTHrP type I receptor.

15. (Twice Amended) The method according to any one of claims 1 to 10 or 12 to 13, wherein the substance that binds to a ligand of PTH receptor or PTHrP

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER L.L.P.

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

receptor to inhibit binding between the ligand and the receptor is chosen from at least one of an anti-PTHrP antibody and an anti-PTH antibody.

16. (Twice Amended) The method according to claim 15, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is an anti-PTHrP antibody.

17. (Amended) The method according to claim 16, wherein the anti-PTHrP antibody is a humanized anti-PTHrP antibody.

18. (Amended) The method according to claim 2, wherein the disease is chosen from at least one of

a) secondary hyperparathyroidism and

b) primary hyperparathyroidism.

19. (Amended) The method according to claim 10, wherein the disease mediated by PTH or PTHrP-cytokine cascade is chosen from at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

20. (Amended) The method according to claim 14, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from at least one of an anti-PTHrP antibody and an anti-PTH antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com